Innovative Neuromodulation Aneuvo's flagship ExaStim® system is a non-invasive neuromodulation device with CE Mark approval and FDA Breakthrough Device Designation, indicating high potential for growth in the US and European markets focused on spinal cord injury treatments.

Recent Funding Boost The company recently secured $22 million in Series C funding, signaling strong investor confidence and providing resources for market expansion, commercialization efforts, and further R&D to accelerate sales of its innovative medical device.

Recognition and Awards Winning the 22nd National Innovation Award in Taiwan highlights global recognition of Aneuvo's technological advancements, opening doors for international sales partnerships and collaborations within advanced medical technology markets.

Strategic Clinical Trials Launching US clinical studies of ExaStim underscores the company’s focus on regulatory approval and proof of safety and effectiveness, which can facilitate trust-building with healthcare providers and accelerate adoption in clinical settings.

Market Diversification Opportunities Participation in international events like RehaCare and ISCoS demonstrates active engagement with industry stakeholders and potential distributors, paving the way for expanding sales channels in the rehabilitation and neuromodulation sectors.